Cell-derived Extracellular Matrix as maintaining Biomaterial for adipogenic differentiation

Abstract

The extracellular matrix (ECM) naturally surrounds cells in humans, and therefore represents the ideal biomaterial for tissue engineering. ECM from different tissues exhibit different composition and physical characteristics. Thus, ECM provides not only physical support but also contains crucial biochemical signals that influence cell adhesion, morphology, proliferation and differentiation. Next to native ECM from mature tissue, ECM can also be obtained from the in vitro culture of cells. In this study, we aimed to highlight the supporting effect of cell-derived- ECM (cdECM) on adipogenic differentiation. ASCs were seeded on top of cdECM from ASCs (scdECM) or pre-adipocytes (acdECM). The impact of ECM on cellular activity was determined by LDH assay, WST I assay and BrdU assay. A supporting effect of cdECM substrates on adipogenic differentiation was determined by oil red O staining and subsequent quantification. Results revealed no effect of cdECM substrates on cellular activity. Regarding adipogenic differentiation a supporting effect of cdECM substrates was obtained compared to control. With these results, we confirm cdECM as a promising biomaterial for adipose tissue engineering.

Towards a standardized multi-tissue decellularization protocol for the derivation of extracellular matrix materials

“…Most remarkably, ECM may be derived from different organs or tissues to recreate specific cellular microenvironments in composition and/or structure. [1][2][3] ECM biomaterials are currently used for both research applications (e.g., substrates for cell growth, [4][5][6][7] microfluidic cell culture systems, 8 ECM-based bio-inks, [9][10][11] drug screening, [12][13][14] cancer studies [15][16][17][18][19] etc.) and in the clinic as implantable or injectable materials.…”

“…1–3 ECM biomaterials are currently used for both research applications ( e.g. , substrates for cell growth, 4–7 microfluidic cell culture systems, 8 ECM-based bio-inks, 9–11 drug screening, 12–14 cancer studies 15–19 etc. ) and in the clinic as implantable or injectable materials.…”